What after John Neylan’s Insider Unload of Keryx Biopharmaceuticals, Inc. (KERX) Stock?; Seacoast Banking of Florida (SBCF) Had 6 Analysts Last Week

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Logo

Seacoast Banking Corporation of Florida (NASDAQ:SBCF) Ratings Coverage

Among 9 analysts covering Seacoast Banking Co. of Florida (NASDAQ:SBCF), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Seacoast Banking Co. of Florida had 23 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Hold” rating by Sandler O’Neill given on Thursday, January 4. The company was upgraded on Thursday, January 11 by Sandler O’Neill. The stock of Seacoast Banking Corporation of Florida (NASDAQ:SBCF) earned “Outperform” rating by Hovde Group on Wednesday, May 11. The company was maintained on Friday, January 26 by FBR Capital. Zacks upgraded Seacoast Banking Corporation of Florida (NASDAQ:SBCF) on Thursday, August 27 to “Sell” rating. As per Monday, January 8, the company rating was maintained by SunTrust. The stock of Seacoast Banking Corporation of Florida (NASDAQ:SBCF) earned “Market Perform” rating by Hovde Group on Tuesday, September 6. On Friday, January 12 the stock rating was maintained by Hovde Group with “Hold”. The firm has “Buy” rating by SunTrust given on Monday, February 13. The rating was maintained by Wood with “Market Perform” on Friday, August 28. See Seacoast Banking Corporation of Florida (NASDAQ:SBCF) latest ratings:

07/02/2018 Broker: Hovde Group Old Rating: Market Perform New Rating: Outperform Upgrade
30/01/2018 Broker: Guggenheim Rating: Hold New Target: $28.0 Maintain
26/01/2018 Broker: FBR Capital Rating: Buy Maintain
12/01/2018 Broker: Hovde Group Rating: Hold New Target: $30.0 Maintain
11/01/2018 Broker: Sandler O’Neill Rating: Buy Upgrade
08/01/2018 Broker: SunTrust Rating: Buy New Target: $30.0 Maintain
04/01/2018 Broker: Sandler O’Neill Rating: Hold New Target: $27.0 Maintain
03/01/2018 Broker: Hovde Group Rating: Hold New Target: $27.0 Maintain
28/11/2017 Broker: SunTrust Rating: Buy New Target: $29.0 Maintain

Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals has $18 highest and $1.80 lowest target. $8.72’s average target is 90.81% above currents $4.57 stock price. Keryx Biopharmaceuticals had 37 analyst reports since July 23, 2015 according to SRatingsIntel. Ladenburg Thalmann maintained the stock with “Buy” rating in Tuesday, August 2 report. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has “Market Perform” rating given on Tuesday, August 2 by FBR Capital. The rating was initiated by Citigroup with “Sell” on Thursday, September 3. On Monday, August 10 the stock rating was downgraded by Roth Capital to “Buy”. The rating was maintained by BTIG Research on Thursday, August 6 with “Sell”. The rating was upgraded by Citigroup to “Neutral” on Wednesday, January 11. The company was maintained on Friday, February 26 by Stifel Nicolaus. The firm has “Buy” rating by Maxim Group given on Thursday, July 27. The firm earned “Market Perform” rating on Wednesday, September 9 by Raymond James. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) earned “Buy” rating by Maxim Group on Thursday, July 20.

Since October 30, 2017, it had 0 insider purchases, and 16 insider sales for $309,524 activity. Shares for $3,532 were sold by Adams Brian. Holmes Scott A also sold $15,569 worth of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) shares. Madison Greg also sold $24,452 worth of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) shares. Neylan John F. sold $27,186 worth of stock or 5,652 shares. Shares for $44,064 were sold by Carberry Christine A. on Thursday, January 18.

John Neylan, an insider, who’s the present Chief Medical Officer of Keryx Biopharmaceuticals Inc made a sale of 1,111 shares of the firm worth around $5,099 U.S Dollars based on a market stock price of 4.6 U.S Dollars per each share. Now, John Neylan has 155,625 shares or 0.13% of the Company’s total market cap.

Investors sentiment decreased to 1.02 in Q4 2017. Its down 0.48, from 1.5 in 2017Q3. It fall, as 20 investors sold Keryx Biopharmaceuticals, Inc. shares while 32 reduced holdings. 20 funds opened positions while 33 raised stakes. 74.81 million shares or 1.05% less from 75.60 million shares in 2017Q3 were reported. Chicago Equity Prtn Limited Liability Corporation stated it has 0.05% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Employees Retirement Association Of Colorado owns 32,231 shares. Old West Inv Management Ltd Limited Liability Company holds 1.65% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) or 621,574 shares. Great West Life Assurance Can holds 0% or 10,000 shares in its portfolio. Baupost Lc Ma invested in 25.79 million shares or 1.19% of the stock. Wells Fargo And Com Mn reported 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Proshare Advsr stated it has 0% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Amer Intl stated it has 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Principal Fin invested 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Zurcher Kantonalbank (Zurich Cantonalbank) has 7,574 shares. Ameritas Investment Prtn Incorporated reported 0% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Fincl Architects stated it has 282 shares. Deutsche National Bank & Trust Ag holds 205,933 shares. Adell Harriman & Carpenter Inc owns 57,204 shares for 0.06% of their portfolio. Gp One Trading Ltd Partnership accumulated 0% or 129,913 shares.

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. The company has market cap of $544.63 million. It markets its lead product Auryxia , an orally available, absorbable, iron medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. It currently has negative earnings. The firm has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan.

Analysts await Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) to report earnings on May, 3. They expect $-0.19 EPS, up 9.52% or $0.02 from last year’s $-0.21 per share. After $-0.26 actual EPS reported by Keryx Biopharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -26.92% EPS growth.

The stock increased 0.88% or $0.04 during the last trading session, reaching $4.57. About 678,984 shares traded. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has declined 32.44% since April 25, 2017 and is downtrending. It has underperformed by 43.99% the S&P500.

Seacoast Banking Corporation of Florida operates as the bank holding firm for Seacoast National Bank that provides community banking services to the commercial, small business, and retail clients in Florida. The company has market cap of $1.31 billion. It offers various transaction and savings deposit products; secured and unsecured loan products, including revolving credit facilities, letters of credit and related financial guarantees, and asset based financing; and securities and annuity products. It has a 28.24 P/E ratio. The firm also provides trust and asset management services to retirement plans, firms, and individuals; treasury management services; brokerage services; and Internet and mobile banking services.

The stock increased 0.83% or $0.23 during the last trading session, reaching $27.96. About 195,869 shares traded. Seacoast Banking Corporation of Florida (NASDAQ:SBCF) has risen 12.55% since April 25, 2017 and is uptrending. It has outperformed by 1.00% the S&P500.

Investors sentiment decreased to 1.48 in 2017 Q4. Its down 0.12, from 1.6 in 2017Q3. It turned negative, as 8 investors sold Seacoast Banking Corporation of Florida shares while 38 reduced holdings. 26 funds opened positions while 42 raised stakes. 34.32 million shares or 3.56% more from 33.14 million shares in 2017Q3 were reported. California Pub Employees Retirement Sys has 48,869 shares for 0% of their portfolio. New York State Common Retirement Fund reported 0% in Seacoast Banking Corporation of Florida (NASDAQ:SBCF). Balyasny Asset Mgmt owns 8,673 shares. Quantitative Systematic Strategies Limited Liability Corp has invested 0.17% of its portfolio in Seacoast Banking Corporation of Florida (NASDAQ:SBCF). Citadel Advisors Limited Co owns 23,972 shares or 0% of their US portfolio. Fj Cap Mgmt Lc reported 634,800 shares stake. Parametric Portfolio Assocs Ltd Liability stated it has 18,174 shares. New York-based Millennium Mngmt Limited Com has invested 0.05% in Seacoast Banking Corporation of Florida (NASDAQ:SBCF). Inv Serv Incorporated Wi has 0.56% invested in Seacoast Banking Corporation of Florida (NASDAQ:SBCF) for 23,295 shares. Congress Asset Mgmt Communication Ma owns 71,076 shares. Delta Asset Mngmt Ltd Liability Tn accumulated 0% or 575 shares. 1492 Cap Mgmt Limited Liability Company owns 126,945 shares for 2.5% of their portfolio. King Luther Mngmt Corporation holds 0.03% of its portfolio in Seacoast Banking Corporation of Florida (NASDAQ:SBCF) for 121,770 shares. 18,871 are owned by Raymond James Services Advsr. Royal Bancorp Of Canada invested in 0% or 400 shares.

Since March 7, 2018, it had 0 insider buys, and 1 sale for $175,616 activity. Goldman Roger sold $175,616 worth of stock.

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Institutional Positions Chart